AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12947368 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg/day
Number of subjects: 0
Study 12947368 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg/day
Number of subjects: 0
Study 12947368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10373752 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 10
Study 10373752 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 10
Study 8803371 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 79
Study 8803371 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 79
Study 8803371 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 79
Study 1804650 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-4370 5 mg
Number of subjects: 12
Study 1804650 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-4370 10 mg
Number of subjects: 12
Study 1804650 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-4370 2.5 mg
Number of subjects: 12
Study 1804650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6135506 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue beta-blocker treatment
Number of subjects: 56
Study 6135506 — intervention group
Group type: COMPARATOR
Intervention: Stop beta-blocker treatment
Number of subjects: 56
Study 31535566 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham cardiovascular disease (CVD) risk equation
Number of subjects: 660
Study 31535566 — intervention group
Group type: EXPERIMENTAL
Intervention: UKPDS coronary heart disease (CHD) risk equation
Number of subjects: 660
Study 31535566 — intervention group
Group type: EXPERIMENTAL
Intervention: UKPDS Fatal CHD risk equation
Number of subjects: 660
Study 31535566 — intervention group
Group type: EXPERIMENTAL
Intervention: UKPDS Stroke risk equation
Number of subjects: 660
Study 31535566 — intervention group
Group type: EXPERIMENTAL
Intervention: UKPDS Fatal Stroke risk equation
Number of subjects: 660
Study 30072044 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier-belief counseling intervention (BBCI)
Number of subjects: 245
Study 30072044 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized lifestyle group intervention (SLI)
Number of subjects: 245
Study 30072044 — intervention group
Group type: COMPARATOR
Intervention: Non-treated hanging control group
Number of subjects: 245
Study 27176122 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation by anesthesiologists (ANES)
Number of subjects: 272
Study 27176122 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation by gastroenterologist-led teams (GLT)
Number of subjects: 272
Study 27176122 — intervention group
Group type: COMPARATOR
Intervention: No sedation (PLCB)
Number of subjects: 272
Study 25365188 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 50 mg·kg(‐1) silybin for 15 consecutive days
Number of subjects: 18
Study 25365188 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 50 mg·kg(‐1) silybin
Number of subjects: 18
Study 25365188 — intervention group
Group type: COMPARATOR
Intervention: Control group (no silybin)
Number of subjects: 18
Study 22525777 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Stabilization (TS) exercises
Number of subjects: 37
Study 22525777 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 37
Study 20372991 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin capsules (fed state)
Number of subjects: 0
Study 20372991 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin capsules (fasted state)
Number of subjects: 0
Study 20372991 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin tablets (fed state)
Number of subjects: 0
Study 20372991 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin tablets (fasted state)
Number of subjects: 0
Study 17963629 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ 80/12.5 mg once daily
Number of subjects: 864
Study 17963629 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg once daily
Number of subjects: 864
Study 16308411 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet wrap bandages
Number of subjects: 50
Study 16308411 — intervention group
Group type: COMPARATOR
Intervention: Conventional topically applied ointments
Number of subjects: 50
Study 16308411 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 50
Study 12824660 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 431
Study 12824660 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 431
Study 10482997 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (CD5+ type)
Number of subjects: 63
Study 10482997 — intervention group
Group type: COMPARATOR
Intervention: Group II (CD5- CD10+ type)
Number of subjects: 63
Study 10482997 — intervention group
Group type: COMPARATOR
Intervention: Group III (CD5- CD10- type)
Number of subjects: 63
Study 10482997 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall DLBL cases
Number of subjects: 63
Study 8942454 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine at low serum level range (50-150 ng/ml)
Number of subjects: 56
Study 8942454 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine at medium serum level range (200-300 ng/ml)
Number of subjects: 56
Study 8942454 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine at high serum level range (350-450 ng/ml)
Number of subjects: 56
Study 8942454 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 56
Study 2017535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg
Number of subjects: 55
Study 2017535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.5 mg
Number of subjects: 55
Study 6637819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (ISDN) 50 to 200 micrograms/kg/hour
Number of subjects: 20
Study 6637819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine 0.15 mg/kg
Number of subjects: 20
Study 6637819 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 1 mg/kg after ISDN
Number of subjects: 20
Study 6637819 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 1 mg/kg after hydralazine
Number of subjects: 20
Study 6637819 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide in both groups
Number of subjects: 20
Study 30576336 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) score assessment
Number of subjects: 240
Study 30576336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium count
Number of subjects: 240
Study 28103948 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-tailored, pharmacist-led intervention programme consisting of a structured interview at the pharmacy to identify barriers to adherence and counsel patients.
Number of subjects: 0
Study 28103948 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-tailored, pharmacist-led intervention programme
Number of subjects: 0
Study 26335704 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing Cancer And Living Meaningfully intervention plus usual care
Number of subjects: 0
Study 26335704 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 24245807 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavioral therapy (ICBT) for 10 weeks
Number of subjects: 79
Study 24245807 — intervention group
Group type: COMPARATOR
Intervention: waiting list
Number of subjects: 79
Study 21148119 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 64 mg/day
Number of subjects: 188
Study 21148119 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg/day
Number of subjects: 188
Study 21148119 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 192 mg/day
Number of subjects: 188
Study 21148119 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 384 mg/day
Number of subjects: 188
Study 21148119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 18308157 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection during PCI (n = 312)
Number of subjects: 626
Study 18308157 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment without distal protection (n = 314)
Number of subjects: 626
Study 18308157 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection
Number of subjects: 626
Study 18308157 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 626
Study 17165292 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD) in 3 configurations: (1) without retention pin, (2) with retention pin < 40%, (3) with retention pin > 75%
Number of subjects: 13
Study 17165292 — intervention group
Group type: COMPARATOR
Intervention: Maxillary Occlusal Splint (MOS)
Number of subjects: 13
Study 14592916 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended transsternal thymectomy
Number of subjects: 0
Study 14592916 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11259988 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (256 microg)
Number of subjects: 24
Study 11259988 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg)
Number of subjects: 24
Study 9526578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR) at a dose of 200 mg per os every day for 5 years
Number of subjects: 2972
Study 8345067 — intervention group
Group type: COMPARATOR
Intervention: Short protocol (buserelin 1 mg/day intranasally from cycle day 1 and HMG 2 ampoules/day from day 3 until HCG administration)
Number of subjects: 428
Study 8345067 — intervention group
Group type: EXPERIMENTAL
Intervention: Long protocol (buserelin 1 mg/day intranasally from cycle day 1 for at least 14 days, then HMG 2 ampoules/day added)
Number of subjects: 428
Study 8345067 — intervention group
Group type: EXPERIMENTAL
Intervention: Long protocol
Number of subjects: 428
Study 8345067 — intervention group
Group type: COMPARATOR
Intervention: Short protocol
Number of subjects: 428
Study 3767129 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 ppm O3
Number of subjects: 17
Study 3767129 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 ppm O3
Number of subjects: 17
Study 3767129 — intervention group
Group type: COMPARATOR
Intervention: Filtered Air (FA)
Number of subjects: 17
Study 29455894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for MS-related fatigue, 16-week treatment.
Number of subjects: 91
Study 29455894 — intervention group
Group type: COMPARATOR
Intervention: MS-nurse consultations (control group).
Number of subjects: 91
Study 27398992 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 5 cm H2O
Number of subjects: 194
Study 27398992 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 10 cm H2O
Number of subjects: 194
Study 27398992 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP (less than 1 cm H2O)
Number of subjects: 194
Study 27398992 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 194
Study 24919077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS to M1nonlesioned
Number of subjects: 10
Study 24919077 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS to M1lesioned
Number of subjects: 10
Study 24919077 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study 23333044 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of L-arginine (500 mg, twice daily for two weeks)
Number of subjects: 19
Study 23333044 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation (control)
Number of subjects: 19
Study 21394118 — intervention group
Group type: EXPERIMENTAL
Intervention: Merogel
Number of subjects: 260
Study 21394118 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 260
Study 18312884 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-patch myringoplasty
Number of subjects: 45
Study 18312884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat myringoplasty
Number of subjects: 45
Study 18312884 — intervention group
Group type: EXPERIMENTAL
Intervention: Perichondrium myringoplasty
Number of subjects: 45
Study 16780613 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 16780613 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 20
Study 12788872 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/d AA2500 testosterone gel
Number of subjects: 406
Study 12788872 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d AA2500 testosterone gel
Number of subjects: 406
Study 12788872 — intervention group
Group type: COMPARATOR
Intervention: Testosterone patch
Number of subjects: 406
Study 12788872 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 406
Study 10819821 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol, 50 microg intravaginally every 4 hours
Number of subjects: 123
Study 10819821 — intervention group
Group type: COMPARATOR
Intervention: Extra-amniotic sodium chloride infusion
Number of subjects: 123
Study 8771664 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferons (alpha‐2 and gamma‐interferons) administered in daily doses of 15,000‐25,000 IU/kg and 1500‐2500 IU/kg, respectively.
Number of subjects: 0
Study 8771664 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferons (alpha‐2 and gamma‐interferons)
Number of subjects: 0
Study 1614182 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled amiloride (10(‐3)M), twice daily for two months
Number of subjects: 9
Study 1614182 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control), twice daily for two months
Number of subjects: 9
Study 3886209 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose AVP infusion (25 pmol/min)
Number of subjects: 0
Study 3886209 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose AVP infusion (75 pmol/min)
Number of subjects: 0
Study 3886209 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP infusion
Number of subjects: 0
Study 31650640 — intervention group
Group type: EXPERIMENTAL
Intervention: 2014 study
Number of subjects: 0
Study 29499522 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein point-of-care testing (CRP POCT)
Number of subjects: 58
Study 26971332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia ablation
Number of subjects: 43
Study 26971332 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Number of subjects: 43
Study 24708575 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (4 × 1.3 mg/m2 over 2 weeks; 3-month interval between cycles)
Number of subjects: 44
Study 24708575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 24708575 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 44
Study 22595390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary intervention
Number of subjects: 80
Study 20233185 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine (2 mg)
Number of subjects: 19
Study 20233185 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (1 mg)
Number of subjects: 19
Study 18567973 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 466
Study 18567973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study 16649829 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine treatment
Number of subjects: 7
Study 16649829 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy female volunteers)
Number of subjects: 7
Study 16649829 — intervention group
Group type: COMPARATOR
Intervention: Between-group analysis
Number of subjects: 7
Study 12794211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligase chain reaction (LCR) on first void urine (FVU)
Number of subjects: 29
Study 12794211 — intervention group
Group type: COMPARATOR
Intervention: Cultures of urethral and cervical swabs
Number of subjects: 29
Study 10996756 — intervention group
Group type: EXPERIMENTAL
Intervention: Antispasmodic drugs (Buscopan)
Number of subjects: 481
Study 10996756 — intervention group
Group type: EXPERIMENTAL
Intervention: Buscopan
Number of subjects: 481
Study 10996756 — intervention group
Group type: COMPARATOR
Intervention: Glucagon
Number of subjects: 481
Study 9000826 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (high and low doses)
Number of subjects: 40
Study 9000826 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 40
Study 9000826 — intervention group
Group type: COMPARATOR
Intervention: Both diclofenac sodium and flurbiprofen
Number of subjects: 40
Study 1623700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride rinses with 0.2% neutral sodium fluoride
Number of subjects: 1306
Study 1623700 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 1306
Study 6147693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 484
Study 6147693 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg
Number of subjects: 484
Study 31743309 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time audiovisual feedback training
Number of subjects: 201
Study 31743309 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard CPR education models)
Number of subjects: 201
Study 28165634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 446
Study 28165634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 446
Study 28165634 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 446
Study 25118857 — intervention group
Group type: EXPERIMENTAL
Intervention: GI X-ray
Number of subjects: 1206
Study 25118857 — intervention group
Group type: COMPARATOR
Intervention: GIE-ST
Number of subjects: 1206
Study 23837574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nebulized salbutamol in 4 mL of isotonic saline
Number of subjects: 13
Study 23837574 — intervention group
Group type: COMPARATOR
Intervention: 5 mL of isotonic saline
Number of subjects: 13
Study 21459891 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 190
Study 21459891 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroalbuminuria
Number of subjects: 190
Study 21459891 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic patients
Number of subjects: 190
Study 21459891 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased UACR
Number of subjects: 190
Study 21459891 — intervention group
Group type: EXPERIMENTAL
Intervention: UACR
Number of subjects: 190
Study 18379768 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion MR imaging
Number of subjects: 33
Study 16249073 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (25 mg and 50 mg/day)
Number of subjects: 212
Study 16249073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 14685736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program for caregivers
Number of subjects: 40
Study 14685736 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed)
Number of subjects: 40
Study 10733168 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIRON CMV gB subunit vaccine combined with MF59 adjuvant
Number of subjects: 0
Study 10733168 — intervention group
Group type: COMPARATOR
Intervention: CMVIG manufactured from high titered plasma units
Number of subjects: 0
Study 8737128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 200 mg once daily following a 400 mg loading dose on day 1
Number of subjects: 211
Study 8737128 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 1 g tid plus ofloxacin 200 mg bid
Number of subjects: 211
Study 6713266 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% epinephrine hydrochloride
Number of subjects: 0
Study 6713266 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dipivefrin hydrochloride
Number of subjects: 0
Study 6713266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29395526 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable-syringe jet injector (DSJI)
Number of subjects: 340
Study 29395526 — intervention group
Group type: COMPARATOR
Intervention: Needle-syringe (N-S)
Number of subjects: 340
Study 29395526 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 340
Study 26864851 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based lifestyle behavioural intervention (10 individually tailored sessions over 6 months)
Number of subjects: 160
Study 26864851 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 25630474 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial-oblique probe position
Number of subjects: 100
Study 25630474 — intervention group
Group type: COMPARATOR
Intervention: Short-axis probe position
Number of subjects: 100
Study 23748760 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% trans fatty acids (TFA) dietary supplementation
Number of subjects: 65
Study 23748760 — intervention group
Group type: COMPARATOR
Intervention: 0.04% trans fatty acids (TFA) dietary supplementation (control)
Number of subjects: 65
Study 20937045 — intervention group
Group type: COMPARATOR
Intervention: rifaximin 1200 mg/day
Number of subjects: 77
Study 20937045 — intervention group
Group type: EXPERIMENTAL
Intervention: rifaximin 1200 mg/day plus partially hydrolysed guar gum 5 g/day for 10 days
Number of subjects: 77
Study 19017854 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft Cast application
Number of subjects: 32
Study 16326121 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of salmeterol/fluticasone immediately before allergen challenge (T2)
Number of subjects: 9
Study 16326121 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone combination (50/250 mcg by Diskus) for 1 week and a single dose of salmeterol/fluticasone immediately before allergen challenge (T3)
Number of subjects: 9
Study 16326121 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment and a single dose of placebo immediately before allergen challenge (T1)
Number of subjects: 9